JP2007515949A5 - - Google Patents

Download PDF

Info

Publication number
JP2007515949A5
JP2007515949A5 JP2006539632A JP2006539632A JP2007515949A5 JP 2007515949 A5 JP2007515949 A5 JP 2007515949A5 JP 2006539632 A JP2006539632 A JP 2006539632A JP 2006539632 A JP2006539632 A JP 2006539632A JP 2007515949 A5 JP2007515949 A5 JP 2007515949A5
Authority
JP
Japan
Prior art keywords
tgf
antagonist
cancer
tumor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006539632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/036651 external-priority patent/WO2005050200A2/en
Publication of JP2007515949A publication Critical patent/JP2007515949A/ja
Publication of JP2007515949A5 publication Critical patent/JP2007515949A5/ja
Withdrawn legal-status Critical Current

Links

JP2006539632A 2003-11-13 2004-11-04 スクリーニングアッセイ及び腫瘍治療の方法 Withdrawn JP2007515949A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52039803P 2003-11-13 2003-11-13
US55795104P 2004-03-31 2004-03-31
PCT/US2004/036651 WO2005050200A2 (en) 2003-11-13 2004-11-04 Screening assays and methods of tumor treatment

Publications (2)

Publication Number Publication Date
JP2007515949A JP2007515949A (ja) 2007-06-21
JP2007515949A5 true JP2007515949A5 (https=) 2007-12-20

Family

ID=34623132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539632A Withdrawn JP2007515949A (ja) 2003-11-13 2004-11-04 スクリーニングアッセイ及び腫瘍治療の方法

Country Status (13)

Country Link
US (1) US20060015952A1 (https=)
EP (1) EP1682890A2 (https=)
JP (1) JP2007515949A (https=)
KR (1) KR20060127409A (https=)
AR (1) AR046832A1 (https=)
AU (1) AU2004292180A1 (https=)
BR (1) BRPI0416305A (https=)
CA (1) CA2542215A1 (https=)
IL (1) IL174916A0 (https=)
NO (1) NO20062715L (https=)
RU (1) RU2006120483A (https=)
TW (1) TW200526957A (https=)
WO (1) WO2005050200A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053682A2 (en) * 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7412026B2 (en) * 2004-07-02 2008-08-12 The Board Of Regents Of The University Of Oklahoma Phase-contrast x-ray imaging systems and methods
US20080082359A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of State Of Delaware Computational systems for biomedical data
US10503872B2 (en) 2006-09-29 2019-12-10 Gearbox Llc Computational systems for biomedical data
US10095836B2 (en) * 2006-09-29 2018-10-09 Gearbox Llc Computational systems for biomedical data
US20080091730A1 (en) * 2006-09-29 2008-04-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10546652B2 (en) * 2006-09-29 2020-01-28 Gearbox Llc Computational systems for biomedical data
US20080082367A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080082583A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10068303B2 (en) 2006-09-29 2018-09-04 Gearbox Llc Computational systems for biomedical data
US20080109484A1 (en) * 2006-09-29 2008-05-08 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US7853626B2 (en) 2006-09-29 2010-12-14 The Invention Science Fund I, Llc Computational systems for biomedical data
US8122073B2 (en) 2006-09-29 2012-02-21 The Invention Science Fund I Computational systems for biomedical data
US8491890B2 (en) * 2008-07-09 2013-07-23 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
WO2010065954A2 (en) 2008-12-05 2010-06-10 Abraxis Bioscience, Llc Sparc binding peptides and uses thereof
US20120294868A1 (en) * 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
AU2010277554B2 (en) * 2009-07-30 2015-02-19 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
EP2494355A4 (en) * 2009-10-30 2013-05-01 Merck Sharp & Dohme PCSK9 IMMUNOASSAY
ME02464B (me) * 2010-03-12 2017-02-20 Genzyme Corp Kombinovana terapija za lečenje raka dojke
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US12156912B2 (en) 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
KR101479543B1 (ko) * 2013-03-15 2015-01-07 서강대학교산학협력단 Ｔｆｇ－ｔｅｃ 융합 컨스트럭트를 이용한 종양 질환의 예방 또는 치료용 물질의 스크리닝 방법 및 이의 용도
CN106573977B (zh) 2014-04-27 2020-08-07 菲姆威有限公司 针对ceacam1的人源化抗体
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3356512B1 (en) 2015-10-02 2021-03-31 Wake Forest University Health Sciences, Inc. Methods and apparatus for modeling cancer metastasis in vitro
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2019152767A1 (en) 2018-02-02 2019-08-08 Wake Forest University Health Sciences Organoids related to immunotherapy and methods of preparing and using the same
US12134645B2 (en) 2018-08-21 2024-11-05 Albert Einstein College Of Medicine Monoclonal antibodies against human tim-3
WO2020124084A1 (en) * 2018-12-15 2020-06-18 The Brigham And Women's Hospital, Inc. Augmented digital microscopy for lesion analysis
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5087799A (en) * 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
AU2001233246A1 (en) * 2000-02-04 2001-08-14 California Pacific Medical Center Research Institute Novel use of ribozymes to block gene expression
US20010046502A1 (en) * 2000-02-04 2001-11-29 The Board Of Trustees Of The University Of Illinois Animal model for testing immunotherapies of spontaneous metastatic disease
CA2298737A1 (en) * 2000-02-10 2001-08-10 Manikkam Suthanthiran 2167334tgf-.beta. antagonists to inhibit tumor cell formation or progression
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta

Similar Documents

Publication Publication Date Title
JP2007515949A5 (https=)
Halvorson et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone
RU2006120483A (ru) Скрининг-анализы и способы лечения опухоли
Ta et al. Osteosarcoma treatment: state of the art
Abdollahi et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis
Higo et al. Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy
Kim et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer
Kuefner et al. DNA double-strand breaks and their repair in blood lymphocytes of patients undergoing angiographic procedures
RU2748549C2 (ru) Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
Xiao et al. Postoperative tumor treatment strategies: From basic research to clinical therapy
AU2017214230A1 (en) Copanlisib biomarkers
Hayat Brain metastases from primary tumors, volume 3: epidemiology, biology, and therapy of melanoma and other cancers
Wang et al. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging
Waterhouse et al. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers
Hiratsuka et al. Hepato‐entrained B220+ CD11c+ NK1. 1+ cells regulate pre‐metastatic niche formation in the lung
Sobol et al. Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma
Radu-Cosnita et al. Anti-chloride intracellular channel protein 1 (CLIC1) antibodies induce tumour necrosis and angiogenesis inhibition on in vivo experimental models of human renal cancer
BRPI0715062A2 (pt) mÉtodos para determinar uma resposta de um indivÍduo mamÍfero que tem cÉlulas de tumor de melanoma ao tratamento com um agente inibidor de melanoma, para avaliar a eficÁcia de um agente inibidor de melanoma para tratar melanoma em um indivÍduo mamÍfero que tem melanoma, para determinar se um paciente deve continuar a receber tratamento com um agente inibidor de melanoma e para identificar agente que tÊm utilidade no tratamento de melanoma
JP2025537840A (ja) 選択的エストロゲン受容体分解薬（ｓｅｒｄ）による乳がんの治療方法
Buumba et al. A critical review on recent development of techniques and drug targets in the management of breast cancer
Dreicer et al. A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
Kawaragi et al. Teriparatide does not exacerbate bone metastases in breast cancer bone metastasis model
Aung et al. Osteogenic sarcoma in children and young adults
CN109069632A (zh) 用于治疗结直肠癌的雷莫芦单抗和merestinib的组合
Zhang et al. Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human MUC1 and CA199 monoclonal antibodies on pancreatic cancer in vitro and in vivo